Table 1.
Distribution of clinicopathologic factors and mean weighted Metasite Scores by breast cancer subtype
| Triple negative | HR+/HER2- | HER2+ | Total | |||||
|---|---|---|---|---|---|---|---|---|
| # (n = 200) | Weighted % | # (n = 297) | Weighted % | # (n = 103) | Weighted % | # (n = 600) | Weighted % | |
| Age (years) | ||||||||
| <=40 | 42 | 22.7% | 33 | 10.8% | 14 | 13.2% | 89 | 14.4% |
| 41–50 | 77 | 40.6% | 96 | 32.9% | 39 | 39.7% | 212 | 36.1% |
| 51–60 | 53 | 24.1% | 102 | 35.6% | 30 | 28.4% | 185 | 31.3% |
| >60 | 28 | 12.6% | 66 | 20.7% | 20 | 18.8% | 114 | 18.2% |
| Premenopausal | 107 | 56.4% | 129 | 43.3% | 46 | 45.8% | 282 | 47.3% |
| Central ER/PR IHC | ||||||||
| ER-positive | 0 | 0% | 264 | 90.5% | 57 | 65.7% | 321 | 61.7% |
| PR-positive | 0 | 0% | 273 | 91.8% | 47 | 54.8% | 320 | 60.7% |
| Tumor size | ||||||||
| <=2 cm | 83 | 44.0% | 157 | 54.4% | 44 | 45.4% | 284 | 50.1% |
| 2.1 to 5.0 cm | 108 | 52.1% | 131 | 42.1% | 53 | 50.6% | 292 | 46.2% |
| >5 cm | 9 | 3.9% | 9 | 3.5% | 6 | 4.0% | 24 | 3.7% |
| Axillary nodal status | ||||||||
| Node negative | 148 | 80.9% | 145 | 54.3% | 63 | 67.9% | 356 | 63.8% |
| 1–3 positive nodes | 52 | 19.1% | 152 | 45.7% | 40 | 32.1% | 244 | 36.2% |
| Central grade | ||||||||
| Low | 2 | 1.1% | 77 | 27.7% | 6 | 8.0% | 85 | 17.2% |
| Intermediate | 18 | 9.0% | 141 | 48.8% | 28 | 30.9% | 187 | 35.0% |
| High | 180 | 89.9% | 79 | 23.5% | 69 | 61.1% | 328 | 47.8% |
| Recurrence Score | ||||||||
| <18 | 0 | 0% | 153 | 54.1% | 13 | 17.7% | 166 | 33.3% |
| 18–30 | 1 | 0.5% | 94 | 31.5% | 10 | 13.3% | 105 | 20.0% |
| >30 | 199 | 99.5% | 50 | 14.4% | 80 | 69.0% | 329 | 46.7% |
| Treatment arm | ||||||||
| AT | 89 | 48.8% | 170 | 51.4% | 51 | 47.2% | 310 | 50.0% |
| AC | 111 | 51.2% | 127 | 48.6% | 52 | (58.8%) | 290 | 50.0% |
| MetaSite Score | ||||||||
| Weighted mean | – | 23.8 | – | 16.1 | – | 26.2 | – | 19.9 |
ER/PR/HER2 classification: 2/600 cases did not have central immunohistochemistry (IHC) available, but local IHC and gene expression results were concordant for these two cases, so they were included and classified based on those results (one case HR+/HER2- and one case TN). ER/PR was classified as positive for Allred Score of 3 or higher as described in ref. 49 HER2 expression was classified in a central lab as positive if 3 + by IHC or FISH amplification by 2007 ASC0-CAP guidelines48
AT doxorubicin/docetaxel, AC doxorubicin/cyclophosphamide